September 29, 2024--(BUSINESS WIRE)--SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a major expansion of its small molecule and peptide ...

LP ("SK Capital"), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, announced today that it has completed the sale of Florachem Corporation ...

SK Biopharma announced on the 17th that its U.S.-based research subsidiary, SK Life Sciences Labs ... development of new drug candidates based on small molecule compounds and targeted protein ...

Companies operating in the life sciences industry continue to face distinct challenges in 2022 mainly due to socio-political developments, trade restrictions, sanctions, inflation, and the lingering ...

Korea-based SK Life Sciences has scored approval from the FDA in the US for its anti-epileptic drug Xcopri, as a treatment for partial-onset seizures in adults. The approval is based on results from ...